Hepatocellular Carcinoma Non-resectable Clinical Trials
3 recruiting trials for Hepatocellular Carcinoma Non-resectable. Eligibility criteria explained in plain English.
TrialFinderData lists 3 Hepatocellular Carcinoma Non-resectable clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Every phased trial in this set is Phase 3 (3 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.
The only sponsor on record for these trials is Second Affiliated Hospital of Guangzhou Medical University (3 trials).
The most frequently studied intervention is Lenvatinib Plus I-125 Seed Brachytherapy (procedure, 1 trial), followed by Lenvatinib, Len+DEB-TACE+HAIC.
Track Hepatocellular Carcinoma Non-resectable trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC
This study is conducted to evaluate the efficacy and safety of lenvatinib plus iodine-125 seed brachytherapy (Len-I) compared with lenvatinib (Len) alone for patients with...
Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT
This study is conducted to evaluate the efficacy and safety of lenvatinib plus transarterial chemoembolization (TACE) with drug-eluting beads (DEB-TACE) and hepatic artery...
Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC
This study is conducted to evaluate the efficacy and safety of lenvatinib, sintilimab plus TACE (Len-Sin-TACE) compared with lenvatinib plus TACE (Len-TACE) for patients with...
Explore Other Conditions
Frequently Asked Questions
There are currently 3 clinical trials for Hepatocellular Carcinoma Non-resectable, with 3 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Hepatocellular Carcinoma Non-resectable, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 3 Phase 3 trials for Hepatocellular Carcinoma Non-resectable, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.